Unnamed: 0,title,date,stock,sentiment
60067.0,Alimera Sciences Q1 Sales $14.535M Beat $13.760M Estimate,2020-04-29 16:02:00-04:00,ALIM,neutral
60068.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,ALIM,positive
60069.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,ALIM,negative
60070.0,Alimera Sciences Receives $1.8M Loan Under Paycheck Protection Act,2020-04-23 08:10:00-04:00,ALIM,neutral
60071.0,"H.C. Wainwright Reiterates Buy on Alimera Sciences, Lowers Price Target to $14",2020-04-14 07:40:00-04:00,ALIM,negative
60072.0,Alimera Sciences Sees Prelim. Q1 Sales Exceeding $14M,2020-04-13 08:39:00-04:00,ALIM,neutral
60073.0,10 Biggest Price Target Changes For Tuesday,2020-04-07 08:17:00-04:00,ALIM,neutral
60074.0,"B. Riley FBR Maintains Buy on Alimera Sciences, Lowers Price Target to $15",2020-04-07 07:00:00-04:00,ALIM,negative
60075.0,Alimera Sciences 8-K Shows Co. Received Letter From Nasdaq Informing It Has Regained Compliance,2020-03-06 14:07:00-05:00,ALIM,neutral
60076.0,140 Biggest Movers From Yesterday,2020-02-28 05:00:00-05:00,ALIM,neutral
60077.0,100 Stocks Moving In Thursday's Mid-Day Session,2020-02-27 12:24:00-05:00,ALIM,neutral
60078.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,ALIM,positive
60079.0,40 Stocks Moving in Thursday's Pre-Market Session,2020-02-27 07:13:00-05:00,ALIM,neutral
60080.0,21 Stocks Moving In Wednesday's After-Hours Session,2020-02-26 18:03:00-05:00,ALIM,neutral
60081.0,Alimera Sciences shares are trading higher after the company reported Q4 EPS results up from last year and better-than-expected sales results. The company also issued FY19 sales guidance above analyst estimates.,2020-02-26 17:02:00-05:00,ALIM,positive
60082.0,Alimera Sciences FY19 Sales $53.94M Vs. $50.85M Est.,2020-02-26 16:28:00-05:00,ALIM,neutral
60083.0,"Alimera Sciences Q4 EPS $0.08 Up From $(0.27) YoY, Sales $17.348M Beat $14.27M Estimate",2020-02-26 16:26:00-05:00,ALIM,neutral
60084.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,ALIM,negative
60085.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,ALIM,neutral
60086.0,20 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's Session,2020-01-27 12:26:00-05:00,ALIM,neutral
60087.0,48 Biggest Movers From Yesterday,2020-01-08 04:45:00-05:00,ALIM,neutral
60088.0,74 Biggest Movers From Yesterday,2019-12-17 05:35:00-05:00,ALIM,neutral
60089.0,51 Biggest Movers From Yesterday,2019-12-13 04:12:00-05:00,ALIM,neutral
60090.0,Alimera Sciences 13D Filing From Ronald Chez Shows New 5.6% Stake,2019-12-11 10:53:00-05:00,ALIM,neutral
60091.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,ALIM,neutral
60092.0,74 Biggest Movers From Friday,2019-12-09 05:22:00-05:00,ALIM,neutral
60093.0,Alimera Announces Regulatory Approval for ILUVIEN in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis,2019-12-03 08:35:00-05:00,ALIM,positive
60094.0,75 Biggest Movers From Yesterday,2019-12-03 05:48:00-05:00,ALIM,neutral
60095.0,52 Biggest Movers From Wednesday,2019-11-29 05:26:00-05:00,ALIM,neutral
60096.0,Alimera Sciences 13G Shows AIGH Capital Management Holds 9.3% Stake In Co.,2019-11-20 14:20:00-05:00,ALIM,neutral
60097.0,72 Biggest Movers From Yesterday,2019-11-19 04:39:00-05:00,ALIM,neutral
60098.0,44 Stocks Moving In Monday's Mid-Day Session,2019-11-18 12:32:00-05:00,ALIM,neutral
60099.0,"H.C. Wainwright Maintains Buy on Alimera Sciences, Raises Price Target to $15",2019-11-18 09:52:00-05:00,ALIM,neutral
60100.0,70 Biggest Movers From Yesterday,2019-11-15 05:29:00-05:00,ALIM,neutral
60101.0,Alimera Sciences Terminates Equity Purchase Agreement With Lincoln Park Capital Fund,2019-11-13 08:15:00-05:00,ALIM,positive
60102.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,ALIM,neutral
60103.0,Alimera Sciences Announces Board's Approval Of 1-For-15 Reverse Stock Split Ratio,2019-11-07 18:14:00-05:00,ALIM,positive
60104.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,ALIM,neutral
60105.0,"HC Wainwright & Co. Maintains Buy on Alimera Sciences, Lowers Price Target to $1",2019-10-31 07:12:00-04:00,ALIM,negative
60106.0,"Alimera Sciences Q3 EPS $(0.04), Inline, Sales $12.85M Beat $12.79M Estimate",2019-10-29 16:58:00-04:00,ALIM,neutral
60107.0,"The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study",2019-10-29 07:32:00-04:00,ALIM,positive
60108.0,Alimera Sciences Reports Equity Purchase Deal For Up To $20M With Lincoln Park Capital,2019-10-25 08:31:00-04:00,ALIM,neutral
60109.0,Alimera Reports Marketing Authorization for ILUVIEN In Portugal For Treatment Of Non-Infectious Posterior Uveitis,2019-10-03 08:41:00-04:00,ALIM,neutral
60110.0,Alimera Sees Prelim. Q3 Sales Exceeding $12.8M,2019-10-02 08:06:00-04:00,ALIM,neutral
60111.0,Alimera Sciences To Present ILUVIEN Clinical Data At American Academy Of Ophthalmology Annual Meeting Oct. 12-15,2019-10-01 08:24:00-04:00,ALIM,neutral
60112.0,Alimera Expands Deal With Horus Pharma To Including Marketing ILUVIEN In Benelux Countries,2019-09-12 08:19:00-04:00,ALIM,positive
60113.0,Alimera Sciences Board Of Directors Approves Reverse Stock Split And 10b5-1 Stock Purchase Plan For U.S. Executive Management,2019-09-05 08:03:00-04:00,ALIM,positive
60114.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,ALIM,positive
60115.0,Alimera Sciences Launches ILUVIEN In Germany For Non-Infectious Uveitis Indication,2019-09-03 08:09:00-04:00,ALIM,neutral
60116.0,"The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved",2019-08-28 07:31:00-04:00,ALIM,positive
60117.0,Alimera Announces ILUVIEN Regulatory Approval In Australia For The Treatment Of Diabetic Macular Edema,2019-08-05 08:24:00-04:00,ALIM,positive
60118.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,ALIM,negative
60119.0,"The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster",2019-07-31 07:06:00-04:00,ALIM,negative
60120.0,28 Healthcare Stocks Moving In Tuesday's After-Market Session,2019-07-31 04:01:00-04:00,ALIM,neutral
60121.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Tue., July 30, 2019",2019-07-30 13:37:00-04:00,ALIM,positive
60122.0,New 52-Week Lows for Tuesday Morning,2019-07-30 11:07:00-04:00,ALIM,negative
60123.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,ALIM,neutral
60124.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,ALIM,negative
60125.0,Alimera Sciences shares are trading higher after the company received a positive NICE recommendation for non-infectious Posterior Uveitis.,2019-06-20 08:57:00-04:00,ALIM,positive
60126.0,Alimera Reports 3-Year Trial Results For ILUVIEN Support Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment,2019-06-06 08:04:00-04:00,ALIM,positive
60127.0,"Craig-Hallum Initiates Coverage On Alimera Sciences with Buy Rating, Announces $3 Price Target",2019-05-28 08:10:00-04:00,ALIM,neutral
60128.0,"Alimera Sciences Reports Launch Of Direct-To-Patient Marketing Campaign To Raise Awareness, Educate Consumers On Diabetic Macular Edema, ILUVIEN",2019-05-22 08:09:00-04:00,ALIM,neutral
60129.0,"Alimera Sciences Q1 EPS $(0.04), Inline, Sales $12.89M Beat $12.28M Estimate",2019-04-29 16:28:00-04:00,ALIM,neutral
60130.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,ALIM,negative
60131.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,ALIM,negative
60132.0,"Alimera Sciences On Monday Reported Q4 EPS $(0.02) Beat $(0.04) Estimate, Sales $15.114M Beat $12.59M Estimate",2019-02-19 09:17:00-05:00,ALIM,neutral
60133.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2019-02-15 14:00:00-05:00,ALIM,neutral
60134.0,Alimera Sees FY18 GAAP Sales $45M vs $43.6M Est.,2019-01-07 08:55:00-05:00,ALIM,neutral
60135.0,"Alimera Sciences 8-K Shows CEO Daniel Myers To Retire, Will Serve As Non-Exec Chair; CFO Richard Eiswirth To Be Promoted To CEO Role",2018-11-29 08:36:00-05:00,ALIM,positive
60136.0,"Alimera Sciences Late Monday Reported Q3 Adj. EPS $(0.05) Beat $(0.06) Estimate, Sales $11.137M Beat $10.98M Estimate",2018-11-06 09:32:00-05:00,ALIM,neutral
60137.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,ALIM,neutral
60138.0,"Alimera Sciences Q2 EPS $(0.06), Inline, Sales $10.9M Beat $10.75M Estimate",2018-07-30 16:30:00-04:00,ALIM,neutral
60139.0,B. Riley FBR: 3 Reasons To Buy Alimera Sciences,2018-06-29 14:50:00-04:00,ALIM,neutral
60140.0,"B. Riley FBR Initiates Coverage On Alimera Sciences with Buy Rating, Announces $2.75 Price Target",2018-06-29 09:21:00-04:00,ALIM,neutral
60141.0,"Alimera Sciences Reports UK National Institute For Health And Care Excellence Will Undertake Partial Review, Appraisal Of Technology Assessment 301 For ILUVIEN Reimbursement",2018-06-11 07:33:00-04:00,ALIM,positive
60142.0,Alimera Sciences Terminates $25M At-the-Market Offering Agreement,2018-06-04 07:34:00-04:00,ALIM,positive
60143.0,Alimera Sciences Announces the Reimbursement of ILUVIEN in Spain,2018-05-31 07:31:00-04:00,ALIM,neutral
60144.0,"Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again",2018-05-11 08:21:00-04:00,ALIM,negative
60145.0,"Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway",2018-05-09 07:48:00-04:00,ALIM,neutral
60146.0,"Alimera Sciences Reports Q4 EPS $(0.09) vs $(0.03) Est., Adj. EBITDA Loss $3.8M, Sales $9.1M vs $12.2M Est.",2018-02-28 16:35:00-05:00,ALIM,negative
60147.0,Alimera Sciences Reports Received Acceptance Of Filing To Obtain Approval For ILUVIEN Non-Infectious Posterior Uveitis Indication In Europe,2018-01-04 07:32:00-05:00,ALIM,positive
60148.0,Alimera Sciences Reports Patients Are Now Being Treated With ILUVIEN In Ireland,2017-12-11 07:30:00-05:00,ALIM,neutral
60149.0,"Alimera Q3 $(0.08) vs $(0.05) Est., Sales $9.78M vs $10.68M Est.",2017-11-01 18:02:00-04:00,ALIM,neutral
60150.0,Alimera Sciences 8-K Shows Registration For $25M Common Stock Sale With HC Wainwright,2017-10-20 16:58:00-04:00,ALIM,neutral
60151.0,Alimera Reports ILUVIEN Is Now Available In Ireland,2017-09-12 16:01:00-04:00,ALIM,neutral
60152.0,"Alimera Sciences Reports Co. Cancelled Previously-Announced Presentation, Webcast At Rodman & Renshaw Global Investment Conference Sept. 12, Cites 'Sever Tropical Storm Impacting Southeast'",2017-09-11 16:05:00-04:00,ALIM,negative
60153.0,Alimera Sciences Signs Agreement With Horus Pharma S.A.S As Exclusive Distributor of ILUVIEN in France,2017-08-29 16:05:00-04:00,ALIM,positive
60154.0,Alimera Sciences Announces UK Medicines and Healthcare Products Regulatory Agency Gives Final Approval To Reuce Size Of ILUVIEN Registry Safety Study,2017-07-19 16:31:00-04:00,ALIM,positive
60155.0,Alimera Sciences Reports ILUVIEN Now Being Given To Patients In Italy,2017-07-12 09:46:00-04:00,ALIM,neutral
60156.0,"UPDATE: pSivida Says Sales-Based Royalty Payments To Co. Will Start At 2%, Increases To 6% Upon Earliest Of 3 Events, Will Increase To 8% Based On ILUVIEN Sales In Excess Of $75M In Any Calendar Year",2017-07-10 16:22:00-04:00,ALIM,positive
60157.0,UPDATE: pSivida Offers Key Terms Of Restructured Global Licensing Deal For ILUVIEN: Co. Grants Alimera Rights To Durasert In EMEA Under ILUVIEN Trademark In Exchange For Tiered Sales-Based Royalty Payments,2017-07-10 16:19:00-04:00,ALIM,positive
60158.0,"Alimera Sciences Reports Q1 Adj. EBITDA Loss $3.7M vs $9.4M in Same Qtr. Last Year, EPS $(0.10) vs $(0.08) Est., Sales $6.618M vs $9.4M Est.",2017-05-08 17:00:00-04:00,ALIM,negative
60159.0,"Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored",2017-04-30 12:59:00-04:00,ALIM,neutral
60160.0,"Benzinga's Top Upgrades, Downgrades For April 27, 2017",2017-04-27 09:24:00-04:00,ALIM,positive
60161.0,"Rodman & Renshaw Initiates Coverage On Alimera Sciences with Buy Rating, Announces $4.00 Price Target",2017-04-27 08:10:00-04:00,ALIM,neutral
60162.0,Alimera Sciences Signs Agreement With Brill Pharma As Exclusive Distributor Of ILUVIEN In Spain,2017-03-13 07:32:00-04:00,ALIM,positive
60163.0,"Alimera Sciences, Knight Therapeutics Report Filing of New Drug Submission for Iluvien in Canada",2017-02-22 08:13:00-05:00,ALIM,neutral
60164.0,Armistice Capital Reports 5.2% Stake In Alimera Sciences,2017-01-19 16:49:00-05:00,ALIM,neutral
60165.0,Stonepine Capital Reports 5.4% Passive Stake in Alimera Sciences in 13G,2016-11-17 14:52:00-05:00,ALIM,positive
60166.0,"Alimera Sciences Reports Q3 Loss/Share $0.16 vs Est Loss/Share $0.11, Rev $8.298M vs $10.53M Est",2016-11-02 16:37:00-04:00,ALIM,neutral
60167.0,"Alimera Sciences Reports Facility Increased to $45M, Interest Only Repayment Period Extended Up to 18 Mos.",2016-10-20 16:43:00-04:00,ALIM,positive
60168.0,12 Biggest Mid-Day Gainers For Friday,2016-09-16 12:39:00-04:00,ALIM,neutral
60169.0,Benzinga's Top Upgrades,2016-09-16 08:44:00-04:00,ALIM,positive
60170.0,Cowen & Co. Upgrades Alimera Sciences to Outperform,2016-09-16 06:18:00-04:00,ALIM,neutral
60171.0,Great Point Partners Reports 5.12% Passive Stake in Alimera Sciences in 13G,2016-08-22 16:44:00-04:00,ALIM,positive
60172.0,Alimera Sciences Prices 18M Shares At $1.40/Share,2016-08-11 08:44:00-04:00,ALIM,positive
60173.0,Alimera Shares Down 11% After Announcing Offering,2016-08-10 16:15:00-04:00,ALIM,positive
60174.0,Alimera Sciences Proposes Public Offering of Common Stock,2016-08-10 16:03:00-04:00,ALIM,neutral
60175.0,20 Biggest Mid-Day Losers For Thursday,2016-08-04 13:05:00-04:00,ALIM,negative
60176.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-08-04 08:35:00-04:00,ALIM,neutral
60177.0,"Alimera Sciences Reports Q2 Adj. EPS $(0.17) vs $(0.19) Est., Sales ~$9.6M vs $8.42M Est.",2016-08-03 17:44:00-04:00,ALIM,neutral
60178.0,Option Alert: ALIM Jan17 2.5 Calls Sweep: 753 @  ASK  $0.65: 953 traded vs 1253 OI:  Earnings 8/3 After Close  $2.02 Ref,2016-07-29 13:34:00-04:00,ALIM,positive
60179.0,Alimera Sciences Spikes to High on Volume,2016-07-28 14:55:00-04:00,ALIM,neutral
60180.0,Alimera Sciences +15% Premarket @$1.95,2016-07-27 07:29:00-04:00,ALIM,neutral
60181.0,Mid-Afternoon Market Update: Crude Oil Drops Below $43; Linear Technology Shares Spike Higher,2016-07-26 15:24:00-04:00,ALIM,negative
60182.0,18 Biggest Mid-Day Gainers For Tuesday,2016-07-26 12:36:00-04:00,ALIM,neutral
60183.0,Mid-Day Market Update: Dow Falls 0.5%; EXACT Sciences Shares Rise Following Strong Q2 Results,2016-07-26 12:06:00-04:00,ALIM,positive
60184.0,Mid-Morning Market Update: Markets Mostly Higher; Caterpillar Tops Q2 Views,2016-07-26 10:18:00-04:00,ALIM,positive
60185.0,Alimera Sciences Reports Prelim Q2 Rev. $9.3-$9.5M vs. 7.24M,2016-07-26 07:37:00-04:00,ALIM,neutral
60186.0,Stocks Hitting 52-Week Lows,2016-07-22 10:41:00-04:00,ALIM,negative
60187.0,Cowen & Company Downgrades Alimera Sciences to Market Perform,2016-05-06 04:41:00-04:00,ALIM,neutral
60188.0,"Alimera Sciences Reports Q1 EPS $(0.22) vs. Est. $(0.18), Rev. $4.1M vs. Est. $5.83M",2016-05-04 16:54:00-04:00,ALIM,neutral
60189.0,Mid-Afternoon Market Update: Dow Falls 100 Points; Sarepta Therapeutics Shares Drop Following Release of FDA Briefing Documents on Eteplirsen,2016-04-21 14:38:00-04:00,ALIM,neutral
60190.0,"Watch Small Cap Biotech Shares On Alimera Halts, Companies up 5% Or Higher On The Day Include Inotek Pharmaceuticals, Avalanch Biotech, Opththotech",2016-04-21 12:13:00-04:00,ALIM,positive
60191.0,"UPDATE: Alimera Shares Move Lower from Session Highs, Now Up 77% to ~$3.34",2016-04-21 12:11:00-04:00,ALIM,neutral
60192.0,"pSividia Shares Trading Up $0.33 To $3.45/Share up 11% On The Day, Possibly In Sympathy With Alimera Sciences",2016-04-21 12:11:00-04:00,ALIM,positive
60193.0,Shares of Alimera Sciences Resume Trade Following Second Circuit Breaker Halt,2016-04-21 12:11:00-04:00,ALIM,positive
60194.0,"Alimera Shares Resume Trade To High Of $5.15, Now At $4.12/Share",2016-04-21 12:06:00-04:00,ALIM,positive
60195.0,BZ NOTE: Alimera Sciences CEO Dan Myers Was Expected to Appear on FBN's Varney & Co. at 11:45 a.m. EDT,2016-04-21 12:05:00-04:00,ALIM,positive
60196.0,"Shares of Alimera Halted on Circuit Breaker, Up 34.5%",2016-04-21 12:01:00-04:00,ALIM,positive
60197.0,"Cantor Fitzgerald Maintains Buy on Alimera Sciences, Lowers PT to $5.00",2016-03-04 06:59:00-05:00,ALIM,negative
60198.0,Mid-Morning Market Update: Markets Open Lower; Joy Global Reports Wider-Than-Expected Q1 Loss,2016-03-03 10:06:00-05:00,ALIM,positive
60199.0,"Earnings Scheduled For March 2, 2016",2016-03-02 04:12:00-05:00,ALIM,neutral
60200.0,Mid-Afternoon Market Update: Crude Oil Slides Over 2%; MannKind Shares Dip On Termination Of Afrezza Deal With Sanofi,2016-01-05 15:07:00-05:00,ALIM,negative
60201.0,Mid-Day Market Update: Dow Falls 50 Points; Smith & Wesson Shares Gain Following Strong Guidance,2016-01-05 12:03:00-05:00,ALIM,positive
60202.0,"Alimera Science Says ILUVIEN J Code J7313 Now Active, Added To Healthcare Common Procedure Coding System, Confirms Pricing Entered Into Part B Avg. Sales Price",2016-01-04 07:31:00-05:00,ALIM,positive
60203.0,Mid-Day Market Update: Crude Oil Drops Over 3%; Sunedison Shares Spike Higher,2015-12-30 12:15:00-05:00,ALIM,negative
60204.0,"Benzinga's M&A Chatter for Thursday December 17, 2015",2015-12-17 18:41:00-05:00,ALIM,neutral
60205.0,"Alimera Sciences Promotes Richard Eiswirth Jr. To CFO, C. Daniel Myers To Remain CEO of Company",2015-12-17 16:52:00-05:00,ALIM,positive
60206.0,UPDATE: Alimera Talking to Investment Banks Regarding Exploring Strategic Alternatives Including Potential Sale,2015-12-17 11:02:00-05:00,ALIM,neutral
60207.0,Alimera Sciences Considering Sale -Reuters,2015-12-17 10:59:00-05:00,ALIM,neutral
60208.0,Alimera Sciences Reports Signing of Deal to Distribute ILUVIEN in The Middle East,2015-12-15 07:32:00-05:00,ALIM,neutral
60209.0,"Alimera Sciences Reports Inline Q3 Loss $0.21, Sales $6.9M Vs Est $6.96",2015-11-05 16:20:00-05:00,ALIM,negative
60210.0,11 Stocks Moving In Friday's After-Hours Session,2015-10-30 16:47:00-04:00,ALIM,neutral
60211.0,13 Stocks To Watch In The Healthcare Space,2015-10-27 14:38:00-04:00,ALIM,neutral
60212.0,Option Alert: $ALIM Nov $2.5 Put; 12500 Contracts @Ask @$0.05,2015-10-22 11:06:00-04:00,ALIM,positive
60213.0,3 Medical Tech Trading Ideas With Upcoming Catalysts,2015-09-29 09:34:00-04:00,ALIM,neutral
60214.0,Alimera Reports Availability of Review Paper on Real World Experience with ILUVIEN,2015-09-28 07:33:00-04:00,ALIM,neutral
60215.0,Alimera Sciences Limited Announces ILUVIEN® Study Results Presented At 15th Euretina Congress,2015-09-24 07:30:00-04:00,ALIM,negative
60216.0,"Alimera Sciences Reports Signing of Exclusive ILUVIEN Distributor Deal for Italy, San Marino, Vatican City",2015-08-13 08:04:00-04:00,ALIM,positive
60217.0,"Alimera Science Reports Q2 Loss $0.19 Vs est Loss $0.22, Sales $5.78M Vs Est $6.49M",2015-08-10 16:09:00-04:00,ALIM,negative
60218.0,Alimera Sciences Reports Q2 EPS $(0.25) vs. Est. $(0.22),2015-08-10 16:07:00-04:00,ALIM,neutral
60219.0,Alimera Sciences Announces They Have Signed Knight Therapeutics As Exclusive Distributor For ILUVIEN For Canada,2015-07-21 07:32:00-04:00,ALIM,positive
60220.0,Alimera Science Reports Q1 Loss $0.27 Vs Est Loss $0.24,2015-05-07 16:27:00-04:00,ALIM,negative
60221.0,Alimera Reports ILUVIEN Now Widely Available for Diabetc Macular Edema Patients Throughout US,2015-04-21 08:07:00-04:00,ALIM,neutral
60222.0,Alimera Reports ILUVIEN Wins EMA in Poland,2015-04-14 08:12:00-04:00,ALIM,positive
60223.0,"Alimera Solutions Reports Q4 EPS -$0.23 Vs Est -$0.17, Sales $1.74M Vs Est $5.11M",2015-03-04 16:29:00-05:00,ALIM,positive
60224.0,"Alimera Shares Volatile Here Following Co. Release Announcing ILUVIEN Has Received Marketing Authorization in Finland, Luxembourg",2015-01-26 14:07:00-05:00,ALIM,positive
60225.0,"Option Alert: ALIM July 2015 $5 Put 5,000 Traded vs 65 OI",2015-01-15 14:40:00-05:00,ALIM,positive
60226.0,Alimera Sciences Announces First Sale of ILUVIEN In Portugal,2015-01-14 11:49:00-05:00,ALIM,neutral
60227.0,pSivida Corp. Reports ILUVIEN Has Been Granted Marketing Authorization In The Netherlands,2014-12-01 15:08:00-05:00,ALIM,positive
60228.0,Alimera Sciences' ILUVIEN Receives Marketing Authorization In The Netherlands,2014-12-01 15:00:00-05:00,ALIM,neutral
60229.0,Alimera Sciences Announces Agreement With Deerfield Management For $50M Financing,2014-11-28 08:31:00-05:00,ALIM,positive
60230.0,Alimera Sciences Announces That The Irish Health Products Regulatory Authority (HPRA) Has Granted Marketing Authorization To ILUVIEN,2014-11-17 11:46:00-05:00,ALIM,positive
60231.0,"Alimera Sciences, Inc. Reports Q3 EPS of $(0.22) vs $(0.70) Est; Revenue of $2.41M vs $3.75M Est",2014-11-06 16:14:00-05:00,ALIM,neutral
60232.0,Alimera Reports Winning of $25M Advance from Hercultes Technology Growth Capital,2014-09-30 13:50:00-04:00,ALIM,positive
60233.0,Alimera Sciences Inc Extends Gains On FDA News,2014-09-29 10:59:00-04:00,ALIM,positive
60234.0,Morning Market Movers ,2014-09-29 09:36:00-04:00,ALIM,neutral
60235.0,Benzinga's Top #PreMarket Gainers,2014-09-29 08:10:00-04:00,ALIM,positive
60236.0,"Alimera Reports Iluvien Approved by FDA Without Restriction, Co. Sees Selling in US During Q1'15",2014-09-29 07:34:00-04:00,ALIM,positive
60237.0,"Shares of Alimera, pSivida Resume Trade; Alimera Now Up 11%, pSivida Now Up 13%",2014-09-26 16:45:00-04:00,ALIM,positive
60238.0,"Shares of Alimera Sciences, pSivida to Resume Trade at 4:45 p.m. EDT",2014-09-26 16:20:00-04:00,ALIM,positive
60239.0,Alimera Confirms FDA Approval for ILUVIEN,2014-09-26 16:15:00-04:00,ALIM,positive
60240.0,"pSividia Confirms FDA Approval for ILUVIEN, Will Earn $25M Milestone",2014-09-26 16:10:00-04:00,ALIM,positive
60241.0,"Alimera, pSivida Have Won FDA Approval for Iluvien in DME",2014-09-26 15:43:00-04:00,ALIM,positive
60242.0,Alimera Sciences Halted: Pending News,2014-09-26 15:34:00-04:00,ALIM,neutral
60243.0,8-K from Alimera Sciences Shows Co. in Sales Pact with Cowen for $35M in Shares,2014-09-22 17:29:00-04:00,ALIM,positive
60244.0,Alimera Sciences' Iluvien Wins Swedish Marketing Authorization for Chronic Diabetic Macular Edema,2014-09-03 07:32:00-04:00,ALIM,positive
60245.0,S-3 from Alimera Sciences Shows Registration for $100M Mixed Securities Shelf,2014-08-11 16:26:00-04:00,ALIM,positive
60246.0,Alimera Sciences Files Up to $100M Mixed Shelf ,2014-08-11 16:25:00-04:00,ALIM,neutral
60247.0,"Alimera Sciences, Inc. Reports Q2 EPS of $(0.16) vs $(0.23) Est; Revenue of $2.20M vs $2.70M Est",2014-08-07 17:02:00-04:00,ALIM,neutral
60248.0,Alimera Sciences' ILUVIEN Receives Marketing Authorization In Denmark for Treatment of Chronic DME,2014-07-31 16:26:00-04:00,ALIM,neutral
60249.0,Alimera Sciences' ILUVIEN Receives Marketing Authorization In Norway for Treatment Of Chronic Diabetic Macular Edema ,2014-07-28 16:03:00-04:00,ALIM,neutral
60250.0,Morning Market Movers ,2014-06-30 09:40:00-04:00,ALIM,neutral
60251.0,Benzinga's Top #PreMarket Gainers,2014-06-30 08:05:00-04:00,ALIM,positive
60252.0,Alimera Sciences Announces Positive Iluvien Outcome For Repeat Use,2014-06-30 07:32:00-04:00,ALIM,positive
60253.0,"Alimera Sciences, Inc. Reports Q1 EPS of $(0.20) vs $(0.25) Est; Revenue of $2.08M vs $1.15M Est",2014-05-08 16:46:00-04:00,ALIM,neutral
60254.0,Alimera Sciences Announces Sept 26th PDUFA Date for ILUVIEN,2014-04-14 07:25:00-04:00,ALIM,neutral
60255.0,Alimera Says Responded To Questions Raised In FDA CRL,2014-03-27 07:02:00-04:00,ALIM,neutral
60256.0,Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast,2014-03-26 10:24:00-04:00,ALIM,neutral
60257.0,"Mid-Day Losers Mar. 7, 2014: PXLW, ALOG, ALSK, NMRX, NLNK, EMAN",2014-03-07 11:34:00-05:00,ALIM,negative
60258.0,"Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower",2014-03-07 09:04:00-05:00,ALIM,negative
60259.0,Alimera Sciences Files to Sell Up to 6.25M Shares at $6.85/Share -S-3,2014-03-07 06:34:00-05:00,ALIM,positive
60260.0,"Alimera Sciences, Inc. Reports Q4 EPS of $(0.24) vs $(0.29) Est; Revenue of $935.0K vs $750.0K Est",2014-02-27 16:11:00-05:00,ALIM,neutral
60261.0,Alimera Sciences Announces $37.5M Private Placement ,2014-01-28 06:51:00-05:00,ALIM,neutral
60262.0,Is The Market On Drugs?,2014-01-16 14:30:00-05:00,ALIM,neutral
60263.0,Morning Market Movers ,2013-12-19 10:04:00-05:00,ALIM,neutral
60264.0,Benzinga's Top #PreMarket Gainers,2013-12-19 08:17:00-05:00,ALIM,positive
60265.0,UPDATE: Alimera Shares Rise 65% After Hours as Co Enters Labeling Discussions with FDA on ILUVIEN,2013-12-18 17:26:00-05:00,ALIM,positive
60266.0,"Alimera Sciences, Inc. Reports Q3 EPS of $(0.04) vs $(0.30) Est; Revenue of $758.0K vs $380.0K Est",2013-11-11 16:11:00-05:00,ALIM,neutral
60267.0,"Cowen & Company Upgrades Alimera Sciences, Inc. to Outperform",2013-10-28 11:28:00-04:00,ALIM,neutral
60268.0,"UPDATE: Alimera Falls 38%, pSivida Down 47% on FDA CRL for ILUVIEN",2013-10-18 08:21:00-04:00,ALIM,neutral
60269.0,Alimera Sciences Receives FDA CRL for ILUVIEN,2013-10-18 06:31:00-04:00,ALIM,neutral
60270.0,"Another Leg Lower in pSivida, Alimera Shares as Traders Await Results of PDUFA",2013-10-17 14:24:00-04:00,ALIM,positive
60271.0,"Northland Securities Initiates Coverage on Alimera Sciences, Inc. with Outperform, $5.00 Target",2013-10-07 17:17:00-04:00,ALIM,positive
60272.0,"Alimera Sciences, Inc. Reports Q2 EPS of $(0.67) Which May Not Compare $(0.24) Est",2013-08-12 16:06:00-04:00,ALIM,neutral
60273.0,"Earnings Scheduled For August 12, 2013",2013-08-12 04:54:00-04:00,ALIM,neutral
60274.0,France's Transparency Commission Issues Positive Opinion For Reimbursement Of ILUVIEN® ,2013-07-24 07:34:00-04:00,ALIM,positive
60275.0,Afternoon Market Gainers ,2013-06-17 12:25:00-04:00,ALIM,neutral
60276.0,A Peek Into The Market Before The Trading Starts,2013-06-14 07:21:00-04:00,ALIM,neutral
60277.0,Alimera Sciences Announces Positive UK Appraisal Recommendation On ILUVIEN ,2013-06-14 06:38:00-04:00,ALIM,positive
60278.0,"Alimera Sciences, Inc. Reports Q4 EPS of $(0.17) vs $(0.23) Est",2013-03-21 16:09:00-04:00,ALIM,neutral
60279.0,"Earnings Scheduled For March 21, 2013",2013-03-21 06:56:00-04:00,ALIM,neutral
60280.0,Alimera Receives Marketing Authorization In Spain for ILUVIEN,2013-01-17 07:32:00-05:00,ALIM,neutral
60281.0,"UPDATE: Oppenheimer Reiterates Outperform Rating, Lowers PT on Alimera Sciences",2012-11-30 10:35:00-05:00,ALIM,negative
60282.0,"Oppenheimer Reiterates Outperform on Alimera Sciences, Inc., Lowers PT to $3.00",2012-11-30 09:41:00-05:00,ALIM,negative
60283.0,U.K.'s NICE Says Alimera's ILUVIEN Not Recommended for Treatment of Chronic Diabetic Macular Edema,2012-11-29 20:38:00-05:00,ALIM,positive
60284.0,Alimera Sciences Reports Q3 EPS $-0.17 vs $-0.18 Est,2012-11-07 16:19:00-05:00,ALIM,neutral
60285.0,Alimera Sciences Closes $40 Million Financing,2012-10-02 17:02:00-04:00,ALIM,neutral
60286.0,Alimera Sciences' ILUVIEN Receives Marketing Authorization in Germany for the Treatment of Chronic Diabetic Macular Edema ,2012-07-26 07:15:00-04:00,ALIM,neutral
60287.0,A Peek Into The Market Before The Trading Starts,2012-07-18 07:27:00-04:00,ALIM,neutral
60288.0,Alimera Sciences Agrees to Sell $40 Million of Convertible Preferred Stock ,2012-07-18 07:03:00-04:00,ALIM,positive
60289.0,Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in Portugal for the Treatment of Chronic Diabetic Macular Edema ,2012-06-05 08:04:00-04:00,ALIM,neutral
60290.0,Earnings Scheduled For May 11,2012-05-11 03:14:00-04:00,ALIM,neutral
60291.0,Alimera Sciences Announces ILUVIEN Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema  ,2012-04-24 08:33:00-04:00,ALIM,neutral
60292.0,Healthcare Investors And Capitalists Actively Looking For The Next Generation Of Market Movers -Reuters,2012-03-23 14:15:00-04:00,ALIM,positive
60293.0,Alimera Sciences Spiking Higher on Heavy Volume; Currently at $4,2012-03-05 13:12:00-05:00,ALIM,neutral
60294.0,Oppenheimer Increases Alimera Sciences PT,2012-02-28 16:38:00-05:00,ALIM,neutral
60295.0,Alimera Sciences Rises 68% Pre-Market on Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN,2012-02-28 08:20:00-05:00,ALIM,positive
60296.0,Benzinga's Top Pre-Market Gainers,2012-02-28 08:07:00-05:00,ALIM,positive
60297.0,"Financial Breakfast: Morning News Summary for February 28, 2012",2012-02-28 07:23:00-05:00,ALIM,neutral
60298.0,Alimera Sciences Announces Positive Outcome to the European Decentralized Procedure for Approval of ILUVIEN for the Treatment of Chronic Diabetic Macular Edema  ,2012-02-28 06:45:00-05:00,ALIM,positive
60299.0,"Benzinga's Microcap Movers for Monday February 27, 2012",2012-02-27 20:30:00-05:00,ALIM,neutral
60300.0,Alimera Sciences Trading 29.8% Higher on Heavy Volume; Currently at $2.22,2012-02-27 11:22:00-05:00,ALIM,neutral
60301.0,"Microcap Movers for Monday December 12, 2011",2011-12-12 17:43:00-05:00,ALIM,neutral
60302.0,"Alimera Sciences Company Spokesperson Says There is No News, No Press Releases to Account for Today's Price Movement",2011-12-12 10:05:00-05:00,ALIM,negative
60303.0,Alimera Sciences Spiking Higher on Heavy Volume,2011-12-12 09:58:00-05:00,ALIM,neutral
60304.0,UPDATE: Credit Suisse Lowering Price Target on Alimera Sciences,2011-11-15 08:14:00-05:00,ALIM,positive
60305.0,"Credit Suisse Downgrades Alimera Sciences to Neutral, PT Lowered to $2",2011-11-15 05:58:00-05:00,ALIM,positive
60306.0,"End-of-Day Market Summary for November 14, 2011",2011-11-14 16:16:00-05:00,ALIM,neutral
60307.0,Citi Downgrading Alimera Sciences ,2011-11-14 08:07:00-05:00,ALIM,neutral
60308.0,Benzinga's Top Downgrades,2011-11-14 07:50:00-05:00,ALIM,positive
60309.0,"Citigroup Downgrades Alimera Sciences to Neutral, Removes PT",2011-11-14 06:11:00-05:00,ALIM,neutral
60310.0,Alimera Sciences Blindsided Again by CRL,2011-11-11 15:01:00-05:00,ALIM,neutral
60311.0,Alimera Sciences Halted for Circuit Breaker,2011-11-11 12:56:00-05:00,ALIM,neutral
60312.0,Alimera Sciences Resumes Trading,2011-11-11 12:55:00-05:00,ALIM,neutral
60313.0,Alimera Sciences Halted for Circuit Breaker,2011-11-11 12:50:00-05:00,ALIM,neutral
60314.0,Alimera Sciences Resumes Trading,2011-11-11 12:50:00-05:00,ALIM,neutral
60315.0,PREVIEW: Alimera Sciences to Resume Trading at 12:50pm,2011-11-11 12:36:00-05:00,ALIM,neutral
60316.0,UPDATE: FDA Said Unable to Approve Alimera Sciences ILUVIEN NDA,2011-11-11 12:02:00-05:00,ALIM,neutral
60317.0,Alimera Sciences Receives Complete Response Letter From FDA for ILUVIEN,2011-11-11 12:00:00-05:00,ALIM,neutral
60318.0,Alimera Sciences Halted for Pending News,2011-11-11 11:48:00-05:00,ALIM,neutral
60319.0,Alimera Sciences Reports Q3 EPS $(0.21) vs $(0.19) Est		,2011-11-03 16:15:00-04:00,ALIM,neutral
60320.0,Alimera Sciences Highlights 36-Month FAME Study Data on ILUVIEN at AAO 2011 Annual Meeting,2011-10-12 07:31:00-04:00,ALIM,positive
60321.0,Rodman & Renshaw Maintain Market Outperform on Alimera Sciences,2011-08-05 09:07:00-04:00,ALIM,neutral
60322.0,Alimera Sciences Reports Q2 EPS $(0.17) vs $(0.19) Est                        ,2011-08-04 16:04:00-04:00,ALIM,neutral
60323.0,Alimera Sciences Appoints James R. Largent to Its Board of Directors  ,2011-08-01 16:19:00-04:00,ALIM,neutral
60324.0,Alimera Sciences Confirms ILUVIEN NDA Resubmission Has Been Accepted by the FDA,2011-06-01 11:41:00-04:00,ALIM,positive
60325.0,36 Month Safety and Efficacy Data From the Phase 3 Fame Study of Iluvien (ALIM),2011-05-05 16:08:00-04:00,ALIM,positive
60326.0,Alimera's New 36-Month Safety and Efficacy Results From the Phase 3 Fame Study of Iluvien in Patients With Diabetic Macular Edema Presented at the 2011 Arvo Annual Meeting (ALIM),2011-05-03 09:17:00-04:00,ALIM,positive
60327.0,Citi Maintains Buy on Alimera Sciences (ALIM),2011-02-04 08:11:00-05:00,ALIM,neutral
60328.0,"Oppenheimer Leaves Alimera Sciences PT, Outperform Rating Unchanged (ALIM)",2011-02-04 08:00:00-05:00,ALIM,neutral
60329.0,CRL for Alimera's Eye drug - Analyst Blog,2010-12-28 09:45:00-05:00,ALIM,neutral
60330.0,Alimera Sciences: Iluvien Approval Delayed By FDA,2010-12-28 07:34:00-05:00,ALIM,positive
60331.0,Afternoon Market Update,2010-12-27 12:05:00-05:00,ALIM,neutral
60332.0,"Google: Analysts' New Targets, Estimates",2010-12-27 09:03:00-05:00,ALIM,neutral
60333.0,"Benzinga's Top Pre-Market NASDAQ Losers (PSDV, TSLA, MGIC, NFLX)",2010-12-27 08:43:00-05:00,ALIM,negative
60334.0,A Peek Into The Market Before The Trading Starts,2010-12-27 08:06:00-05:00,ALIM,neutral
60335.0,Credit Suisse Lowers PT On ALIM,2010-12-27 08:02:00-05:00,ALIM,positive
60336.0,Oppenheimer Has Outperform Rating On Alimera Sciences (ALIM),2010-12-27 07:16:00-05:00,ALIM,neutral
60337.0,Biotech Calendar: Key Dates for December,2010-11-30 07:00:00-05:00,ALIM,neutral
60338.0,Mr. Yilun Jin Resigns as CFO of American Lorain Corporation ,2010-10-14 16:32:00-04:00,ALIM,negative
60339.0,"Rodman & Renshaw Initiates Coverage On ALIM, PUDA",2010-10-11 11:23:00-04:00,ALIM,neutral
60340.0,ALIM: FDA Grants Iluvien NDA Priority Review,2010-08-31 09:11:00-04:00,ALIM,positive
60341.0,Citigroup Believes ALIM’s Risk/Reward Tradeoff Is Favorable,2010-08-18 09:03:00-04:00,ALIM,positive
